Larisa V. Shulzhenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Larisa V. Shulzhenko has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Elena V. Bolotova
Federal State Budgetary Educational Institution of Higher Education “Kuban State Medical University” of the Ministry of Health of the Russian Federation
10 shared publications - Igor V. Pershukov
Южный региональный научный центр сердечно-сосудистой хирургии, Джалал-Абадский государственный университет, Манас; Ошский государственный университет, Ош
7 shared publications - Elena D. Kosmacheva
Kuban State Medical University; Scientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1
6 shared publications - Igor' V. Leshchenko
Ural State Medical University of the Ministry of Health of the Russian Federation
6 shared publications - Irina Vladimirovna Demko
Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
5 shared publications - Sergey Nikolaevich Avdeev
Sechenov First Moscow State Medical University, Moscow, Russia
5 shared publications
Latest Publications
- Open Access
- 10 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 200-207
Drug-induced Lyell’s syndrome: Clinical and pathogenetic aspects and an interdisciplinary approach to therapy (analysis of clinical observation)
Lyell’s syndrome (toxic epidermal necrolysis) is a rare, life-threatening disease with a mortality rate of up to 30–50%, caused by the frequent development of septic complications, dehydration, and electrolyte imbalances. Drugs play a key role in the development of this pathology. Currently, over 100 known trigger drugs are known, including those widely used in medical practice such as nonsteroidal anti-inflammatory drugs, antiepileptic and antigout drugs, sulfonamides, and antibiotics. Moreover, the simultaneous use of several drugs increases the risk of developing Lyell’s syndrome. Less frequently, the disease has been described as occurring in the context of Mycoplasma pneumoniae and herpes simplex virus infection. This paper discusses current theories of toxic epidermal necrolysis pathogenesis, emphasizing the modern clinical features of this pathology: rapid generalization of the process, nonspecific initial symptoms, and a high risk of multiple organ failure. Criteria for assessing the severity and prognosis of the disease are presented. Particular attention is paid to the complexities of treatment due to the lack of a unified patient management protocol. The need for interdisciplinary collaboration between a dermatovenerologist, ophthalmologist, otolaryngologist, combustion specialist, surgeon, and, when treating children, a pediatrician is emphasized. This article presents a case study of a patient with Lyell’s syndrome who had a history of lamotrigine use. Due to the nonspecific nature of her initial symptoms, the disease was misdiagnosed as infectious, leading to the additional prescription of oseltamivir. Errors in patient management after the correct diagnosis was verified are described, and the effectiveness of treatment in the combustion department is highlighted thanks to the collaborative determination of therapeutic strategies in a multidisciplinary consultation.
- 10 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 14,p. 200-207
Open AccessDrug-induced Lyell’s syndrome: Clinical and pathogenetic aspects and an interdisciplinary approach to therapy (analysis of clinical observation)
Lyell’s syndrome (toxic epidermal necrolysis) is a rare, life-threatening disease with a mortality rate of up to 30–50%, caused by the frequent development of septic complications, dehydration, and electrolyte imbalances. Drugs play a key role in the development of this pathology. Currently, over 100 known trigger drugs are known, including those widely used in medical practice such as nonsteroidal anti-inflammatory drugs, antiepileptic and antigout drugs, sulfonamides, and antibiotics. Moreover, the simultaneous use of several drugs increases the risk of developing Lyell’s syndrome. Less frequently, the disease has been described as occurring in the context of Mycoplasma pneumoniae and herpes simplex virus infection. This paper discusses current theories of toxic epidermal necrolysis pathogenesis, emphasizing the modern clinical features of this pathology: rapid generalization of the process, nonspecific initial symptoms, and a high risk of multiple organ failure. Criteria for assessing the severity and prognosis of the disease are presented. Particular attention is paid to the complexities of treatment due to the lack of a unified patient management protocol. The need for interdisciplinary collaboration between a dermatovenerologist, ophthalmologist, otolaryngologist, combustion specialist, surgeon, and, when treating children, a pediatrician is emphasized. This article presents a case study of a patient with Lyell’s syndrome who had a history of lamotrigine use. Due to the nonspecific nature of her initial symptoms, the disease was misdiagnosed as infectious, leading to the additional prescription of oseltamivir. Errors in patient management after the correct diagnosis was verified are described, and the effectiveness of treatment in the combustion department is highlighted thanks to the collaborative determination of therapeutic strategies in a multidisciplinary consultation.
- Open Access
- 10 October 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (9) , 503-510
Small airways disease in bronchial asthma and the role of extrafine inhaled formulations in clinical practice. Resolution of the Expert Council
Small airways disease (SAD) in bronchial asthma (BA) has been characterized in detail, yet it is rarely assessed in routine care and is not reflected in current stepwise treatment algorithms. In the ATLANTIS (Assessment of Small Airways Involvement in Asthma) study, signs of SAD were detectable in 91% of patients with BA, and an oscillometry-based composite score predicted asthma control and exacerbation risk independently of forced expiratory volume in 1 second. The aim of publishing the resolution of the Expert Council was to summarize the evidence on the clinical relevance of SAD, to define the diagnostic methods available in Russian health care, and to clarify the place of extrafine inhaled formulations within the treatment algorithm. SAD should be regarded as a treatable trait of asthma and assessed routinely in patients who do not achieve control. Impulse oscillometry with assessment of R5–R20 (resistance at 5 Hz – 20 Hz), area of reactance (AX) and X5 (reactance at 5 Hz) was endorsed as the method of choice; where IOS is unavailable, FEF25–75 may be used provided forced vital capacity is normal. Extrafine inhaled corticosteroids (ICS) are associated with a higher likelihood of achieving control (odds ratio 1.34; 95% confidence interval 1.22–1.46) and a lower exacerbation rate (rate ratio 0.84, 95% confidence interval 0.73–0.97) at a mean prescribed ICS dose 170 μg/day lower. When control is not achieved on ICS/LABA (long-acting β2-agonist) or ICS/LABA/LAMA (long-acting muscarinic antagonist), switching to an extrafine formulation within the same treatment step should be considered before the ICS dose is increased.
- 10 October 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (9) , 503-510
Open AccessSmall airways disease in bronchial asthma and the role of extrafine inhaled formulations in clinical practice. Resolution of the Expert Council
Small airways disease (SAD) in bronchial asthma (BA) has been characterized in detail, yet it is rarely assessed in routine care and is not reflected in current stepwise treatment algorithms. In the ATLANTIS (Assessment of Small Airways Involvement in Asthma) study, signs of SAD were detectable in 91% of patients with BA, and an oscillometry-based composite score predicted asthma control and exacerbation risk independently of forced expiratory volume in 1 second. The aim of publishing the resolution of the Expert Council was to summarize the evidence on the clinical relevance of SAD, to define the diagnostic methods available in Russian health care, and to clarify the place of extrafine inhaled formulations within the treatment algorithm. SAD should be regarded as a treatable trait of asthma and assessed routinely in patients who do not achieve control. Impulse oscillometry with assessment of R5–R20 (resistance at 5 Hz – 20 Hz), area of reactance (AX) and X5 (reactance at 5 Hz) was endorsed as the method of choice; where IOS is unavailable, FEF25–75 may be used provided forced vital capacity is normal. Extrafine inhaled corticosteroids (ICS) are associated with a higher likelihood of achieving control (odds ratio 1.34; 95% confidence interval 1.22–1.46) and a lower exacerbation rate (rate ratio 0.84, 95% confidence interval 0.73–0.97) at a mean prescribed ICS dose 170 μg/day lower. When control is not achieved on ICS/LABA (long-acting β2-agonist) or ICS/LABA/LAMA (long-acting muscarinic antagonist), switching to an extrafine formulation within the same treatment step should be considered before the ICS dose is increased.
- Open Access
- 8 October 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (5) , 800-809
Prospects of combined biomarker indices for the diagnosis of progressive pulmonary fibrosis in patients with hypersensitivity pneumonitis
Hypersensitivity pneumonitis (HP) is one of the most common interstitial lung diseases (ILDs) and is characterized by the potential development of progressive pulmonary fibrosis (PPF). Alongside established diagnostic criteria for PPF, the search for laboratory biomarkers enabling early detection of PPF in patients with ILD remains an important area of research. The aim to develop a biomarkerbased predictive model for the early diagnosis of PPF in patients with HP. Methods. The study included 85 patients with HP. PPF was diagnosed according to the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society (2022) criteria. Quantitative measurements of biomarkers in serum and bronchoalveolar lavage fluid (BALF) were performed using an Infinite M Nano automated spectrophotometer (Tecan, Austria). Statistical analyses were conducted using SPSS Statistics version 23. Multivariable logistic regression analysis was used to develop predictive models for PPF risk, while the diagnostic performance of biomarkers and derived models was assessed using receiver operating characteristic (ROC) analysis. Results. In patients with HP and PPF, the optimal BALF biomarker cutoff values were 6.37 ng/mL for MMP7 and 521.29 pg/mL for MCP1 (CCL2). The serum biomarker cutoff values were 6.79 ng/mL for MMP7, 17.56 ng/mL for SPD, and 643.59 pmol/L for periostin. The combined BALF index consisting of MMP7 and MCP1 (CCL2) predicted the risk of PPF with a sensitivity of 87.5% and a specificity of 83.0%. The combined serum index including MMP7, SPD, and periostin demonstrated a sensitivity of 84.4% and a specificity of 92.5%. Conclusion. The combined BALF biomarker index MMP7 + MCP1 (CCL2) and the combined serum biomarker index MMP7 + SPD + periostin are highly sensitive and specific tools for the early diagnosis of PPF in patients with HP.
- 8 October 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (5) , 800-809
Open AccessProspects of combined biomarker indices for the diagnosis of progressive pulmonary fibrosis in patients with hypersensitivity pneumonitis
Hypersensitivity pneumonitis (HP) is one of the most common interstitial lung diseases (ILDs) and is characterized by the potential development of progressive pulmonary fibrosis (PPF). Alongside established diagnostic criteria for PPF, the search for laboratory biomarkers enabling early detection of PPF in patients with ILD remains an important area of research. The aim to develop a biomarkerbased predictive model for the early diagnosis of PPF in patients with HP. Methods. The study included 85 patients with HP. PPF was diagnosed according to the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society (2022) criteria. Quantitative measurements of biomarkers in serum and bronchoalveolar lavage fluid (BALF) were performed using an Infinite M Nano automated spectrophotometer (Tecan, Austria). Statistical analyses were conducted using SPSS Statistics version 23. Multivariable logistic regression analysis was used to develop predictive models for PPF risk, while the diagnostic performance of biomarkers and derived models was assessed using receiver operating characteristic (ROC) analysis. Results. In patients with HP and PPF, the optimal BALF biomarker cutoff values were 6.37 ng/mL for MMP7 and 521.29 pg/mL for MCP1 (CCL2). The serum biomarker cutoff values were 6.79 ng/mL for MMP7, 17.56 ng/mL for SPD, and 643.59 pmol/L for periostin. The combined BALF index consisting of MMP7 and MCP1 (CCL2) predicted the risk of PPF with a sensitivity of 87.5% and a specificity of 83.0%. The combined serum index including MMP7, SPD, and periostin demonstrated a sensitivity of 84.4% and a specificity of 92.5%. Conclusion. The combined BALF biomarker index MMP7 + MCP1 (CCL2) and the combined serum biomarker index MMP7 + SPD + periostin are highly sensitive and specific tools for the early diagnosis of PPF in patients with HP.
- Open Access
- 9 September 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (8) , 605-610
Experience with the combined drug (bromhexine + guaifenesin + salbutamol) in patients with acute bronchitis and bronchial obstruction syndrome. Case report
Acute cough is one of the leading reasons for adult patients seeking primary medical care. The most common cause of acute cough is acute bronchitis. Modern domestic and international clinical guidelines agree that acute bronchitis is a self-limiting disease, and the basis of treatment remains symptomatic therapy and informing the patient about the natural course of the disease. The therapeutic strategy is usually aimed at symptomatic relief of cough, reducing the subjective severity of the disease and preventing the unjustified use of antibacterial drugs. The pathogenesis of cough in acute bronchitis is due to a combination of inflammatory infiltration of the bronchial mucosa, impaired mucociliary clearance, increased production of bronchial secretions and the development of transient hypersensitivity of cough receptors. Some patients have temporary bronchial hyperreactivity accompanied by reversible bronchial obstruction, which explains the occurrence of wheezing and episodes of expiratory dyspnea. The multifactorial nature of the pathogenesis of acute bronchitis determines the interest in combination therapy, which includes drug combinations and simultaneously affects various links in the pathogenesis of acute bronchitis. A fixed combination of bromhexine, guaifenesin, and salbutamol provides a pathogenetically sound treatment option for productive cough in acute bronchitis due to a combination of mucolytic, expectorant, and bronchodilating effects. This article presents a retrospective analysis of 2 clinical cases of the use of Bromhexcomb® and Bromhexcomb Expectorant® (in the form of tablets and syrup) containing fixed doses of bromhexine hydrochloride, guaifenesin, and salbutamol sulfate in patients with acute bronchitis and airway obstruction is presented. The drugs have been shown to be highly effective in the treatment of cough. The drugs demonstrated good tolerability, and no adverse reactions were reported. Thus, the combined drug Bromgecomb® and Bromgecomb expectorant® represent a effective and pathogenetically sound treatment option for productive cough in patients with acute bronchitis with bronchial obstructive syndrome. The presence of two dosage forms (tablets and syrup) makes Bromgecomb one of the drugs of choice among other combined drugs.
- 9 September 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (8) , 605-610
Open AccessExperience with the combined drug (bromhexine + guaifenesin + salbutamol) in patients with acute bronchitis and bronchial obstruction syndrome. Case report
Acute cough is one of the leading reasons for adult patients seeking primary medical care. The most common cause of acute cough is acute bronchitis. Modern domestic and international clinical guidelines agree that acute bronchitis is a self-limiting disease, and the basis of treatment remains symptomatic therapy and informing the patient about the natural course of the disease. The therapeutic strategy is usually aimed at symptomatic relief of cough, reducing the subjective severity of the disease and preventing the unjustified use of antibacterial drugs. The pathogenesis of cough in acute bronchitis is due to a combination of inflammatory infiltration of the bronchial mucosa, impaired mucociliary clearance, increased production of bronchial secretions and the development of transient hypersensitivity of cough receptors. Some patients have temporary bronchial hyperreactivity accompanied by reversible bronchial obstruction, which explains the occurrence of wheezing and episodes of expiratory dyspnea. The multifactorial nature of the pathogenesis of acute bronchitis determines the interest in combination therapy, which includes drug combinations and simultaneously affects various links in the pathogenesis of acute bronchitis. A fixed combination of bromhexine, guaifenesin, and salbutamol provides a pathogenetically sound treatment option for productive cough in acute bronchitis due to a combination of mucolytic, expectorant, and bronchodilating effects. This article presents a retrospective analysis of 2 clinical cases of the use of Bromhexcomb® and Bromhexcomb Expectorant® (in the form of tablets and syrup) containing fixed doses of bromhexine hydrochloride, guaifenesin, and salbutamol sulfate in patients with acute bronchitis and airway obstruction is presented. The drugs have been shown to be highly effective in the treatment of cough. The drugs demonstrated good tolerability, and no adverse reactions were reported. Thus, the combined drug Bromgecomb® and Bromgecomb expectorant® represent a effective and pathogenetically sound treatment option for productive cough in patients with acute bronchitis with bronchial obstructive syndrome. The presence of two dosage forms (tablets and syrup) makes Bromgecomb one of the drugs of choice among other combined drugs.
- Open Access
- 14 July 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 158-164
Association of MCP-1, VEGF-A, and IL-10 with progressive pulmonary fibrosis in hypersensitivity pneumonitis
Introduction . Hypersensitivity pneumonitis (HP) is the most common interstitial lung disease (ILD), which is characterized by the development of progressive pulmonary fibrosis (PPF). Aim. To study the relationship between monocyte chemoattractant protein-1 (MCP-1), vascular endothelial growth factor (VEGF-A) and interleukin-10 (IL-10) in serum and PPF criteria in patients with HP. Materials and methods . The study included 51 patients with GP, the diagnosis of PPF was established based on the diagnostic criteria of the American Thoracic Society (2022), and 12 patients with idiopathic pulmonary fibrosis (IPF). Quantitative determination of the level of MCP-1, VEGF-A and IL-10 in the blood serum was performed using Vector-Best kits (Russia) on the enzyme immunoassay analyzer “Hydro Flex” (TECAN, Austria). Statistical data processing was performed using Statistica 10.0 software. Results. Baseline levels of MCP-1 and IL-10 (7.11 ± 2.26 vs. 6.53 ± 2.62 pg/ml) in the blood serum were comparable in IPF and GP with PPF (p = 0.36 and p = 0.18, respectively). MCP-1 levels were significantly higher in IPF and GP with PPF (291.3 ± 68.4 vs. 270.9 ± 54.2 pg/ml) compared to GP without PFF (220,9 ± 42,8 pg/ml; p = 0.005 and p = 0.008). A negative correlation was found between MCP-1 and IL-10 levels and dynamics FVC and DLCO over 12 months. Conclusion . Increased serum MCP-1 and IL-10 levels in patients with PPF in GP are statistically significantly associated with a decrease in FVC ≥ 5% and DLCO ≥ 10% over a 12-month period.
- 14 July 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 158-164
Open AccessAssociation of MCP-1, VEGF-A, and IL-10 with progressive pulmonary fibrosis in hypersensitivity pneumonitis
Introduction . Hypersensitivity pneumonitis (HP) is the most common interstitial lung disease (ILD), which is characterized by the development of progressive pulmonary fibrosis (PPF). Aim. To study the relationship between monocyte chemoattractant protein-1 (MCP-1), vascular endothelial growth factor (VEGF-A) and interleukin-10 (IL-10) in serum and PPF criteria in patients with HP. Materials and methods . The study included 51 patients with GP, the diagnosis of PPF was established based on the diagnostic criteria of the American Thoracic Society (2022), and 12 patients with idiopathic pulmonary fibrosis (IPF). Quantitative determination of the level of MCP-1, VEGF-A and IL-10 in the blood serum was performed using Vector-Best kits (Russia) on the enzyme immunoassay analyzer “Hydro Flex” (TECAN, Austria). Statistical data processing was performed using Statistica 10.0 software. Results. Baseline levels of MCP-1 and IL-10 (7.11 ± 2.26 vs. 6.53 ± 2.62 pg/ml) in the blood serum were comparable in IPF and GP with PPF (p = 0.36 and p = 0.18, respectively). MCP-1 levels were significantly higher in IPF and GP with PPF (291.3 ± 68.4 vs. 270.9 ± 54.2 pg/ml) compared to GP without PFF (220,9 ± 42,8 pg/ml; p = 0.005 and p = 0.008). A negative correlation was found between MCP-1 and IL-10 levels and dynamics FVC and DLCO over 12 months. Conclusion . Increased serum MCP-1 and IL-10 levels in patients with PPF in GP are statistically significantly associated with a decrease in FVC ≥ 5% and DLCO ≥ 10% over a 12-month period.
- 22 October 2025
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 1 (3) , 19-26
Clinical and patient-reported outcomes of triple therapy (budesonide/glycopyrronium bromide/formoterol) in chronic obstructive pulmonary disease: results of the observational MINERVA study
Objective. The evaluation of clinical and patient-reported outcomes in patients with chronic obstructive pulmonary disease (COPD) treated with the triple combination of budesonide/glycopyrronium bromide/formoterol (BUD/GLY/FORM) in real-life clinical practice. Material and methods. The non-interventional MINERVA study (NCT06422676) was conducted in Russia in 2023—2024. Retrospective data were collected for a period of 12 months before the start of therapy. The prospective observation period was 24 weeks from the start of therapy. Results. The study included 200 patients, average age 64.97 years, 58.5% of patients ≥65 years and older, 87.5% of patients were male, 59% were active smokers. The average baseline CAT (COPD Assessment Test) score was 23.80. A total of 137 (68.5%) patients had moderate or severe COPD exacerbations in the previous 12 months. A total of 196 patients completed 24 weeks of treatment. The mean (95% confidence interval (CI)) change in CAR score from baseline was –8.81 (–9.85; –7.76) at week 24 and –5.63 (–6.29; –4.98) at week 12. In patients with severe exacerbations in the past year, it was –11.57 (–14.08; –9.07) and –6.22 (–7.69; –4.76), respectively; in patients with elevated baseline blood eosinophil levels, the change was –9.21 (–12.25; –6.17) and –6.21 (–8.41; –4.01), respectively. A reduction in CAT by ≥2 points by week 24 was achieved in 87% of patients (95% CI 81.53%; 91.33%). The average number of moderate exacerbations per patient decreased from 0.83 to 0.03, severe exacerbations — from 0.44 to 0.02. The therapy was characterized by high compliance, was safe and well tolerated. Conclusion. The use of BUD/GLI/FORM leads to an improvement in the condition of patients with COPD and can significantly reduce the frequency of exacerbations.
- 22 October 2025
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 1 (3) , 19-26
Clinical and patient-reported outcomes of triple therapy (budesonide/glycopyrronium bromide/formoterol) in chronic obstructive pulmonary disease: results of the observational MINERVA study
Objective. The evaluation of clinical and patient-reported outcomes in patients with chronic obstructive pulmonary disease (COPD) treated with the triple combination of budesonide/glycopyrronium bromide/formoterol (BUD/GLY/FORM) in real-life clinical practice. Material and methods. The non-interventional MINERVA study (NCT06422676) was conducted in Russia in 2023—2024. Retrospective data were collected for a period of 12 months before the start of therapy. The prospective observation period was 24 weeks from the start of therapy. Results. The study included 200 patients, average age 64.97 years, 58.5% of patients ≥65 years and older, 87.5% of patients were male, 59% were active smokers. The average baseline CAT (COPD Assessment Test) score was 23.80. A total of 137 (68.5%) patients had moderate or severe COPD exacerbations in the previous 12 months. A total of 196 patients completed 24 weeks of treatment. The mean (95% confidence interval (CI)) change in CAR score from baseline was –8.81 (–9.85; –7.76) at week 24 and –5.63 (–6.29; –4.98) at week 12. In patients with severe exacerbations in the past year, it was –11.57 (–14.08; –9.07) and –6.22 (–7.69; –4.76), respectively; in patients with elevated baseline blood eosinophil levels, the change was –9.21 (–12.25; –6.17) and –6.21 (–8.41; –4.01), respectively. A reduction in CAT by ≥2 points by week 24 was achieved in 87% of patients (95% CI 81.53%; 91.33%). The average number of moderate exacerbations per patient decreased from 0.83 to 0.03, severe exacerbations — from 0.44 to 0.02. The therapy was characterized by high compliance, was safe and well tolerated. Conclusion. The use of BUD/GLI/FORM leads to an improvement in the condition of patients with COPD and can significantly reduce the frequency of exacerbations.
- Open Access
- 9 October 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (5) , 686-693
Changes in the serum level of matrix metalloproteinases and surfactant proteins in patients with hypersensitivity pneumonitis
The most studied biomarkers of progressive pulmonary fibrosis (PPF) are matrix metalloproteinases (MMP) types 1, 7 and 9 and surfactant proteins A and D (SP-A and SP-D). The aim was to study the levels of MMP-1, MMP-7, MMP-9, SP-A and SP-D in the context of diagnosis of idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) and the relationship of these indicators with the PPF criteria. Methods. The study included 65 patients with ILD. Analysis of computed tomography (CT) scans, spirometry, and lung diffusion capacity data were performed. PPF was established based on the diagnostic criteria of the American Thoracic Society (2022). Quantitative determination of serum SP-A levels was performed using Cloud-Clone Corp. kits. (China), SP-D and MMP-7 levels using RDS kits (USA), MMP-1 and MMP-9 levels using RayBiotech kits (USA) on the Hydro Flex enzyme immunoassay (TECAN, Austria). Statistical data processing was performed using Statistica 10.0 software. Results. A relationship between elevated MMP-7 and SP-D levels in HP and PPF criteria was found. No statistically significant differences were found between MMP-7 and SP-D levels in IPF and HP with PPF (9.03 ± 3.1 and 8.47 ± 2.61 ng/ml, respectively; p = 0.42), as well as SP-D (34.51 ± 6.12 ng/ml in IPF and 33.22 ± 8.91 ng/ml in HP with PPF; p = 0.45). Negative correlation was noted between elevated levels of SP-D and MMP-7 with FVC and DLCO during the year. Conclusion. An increase in the levels of MMP-7 and SP-D in the blood serum allows us to consider these indicators for the diagnosis of PPF in HP.
- 9 October 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (5) , 686-693
Open AccessChanges in the serum level of matrix metalloproteinases and surfactant proteins in patients with hypersensitivity pneumonitis
The most studied biomarkers of progressive pulmonary fibrosis (PPF) are matrix metalloproteinases (MMP) types 1, 7 and 9 and surfactant proteins A and D (SP-A and SP-D). The aim was to study the levels of MMP-1, MMP-7, MMP-9, SP-A and SP-D in the context of diagnosis of idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) and the relationship of these indicators with the PPF criteria. Methods. The study included 65 patients with ILD. Analysis of computed tomography (CT) scans, spirometry, and lung diffusion capacity data were performed. PPF was established based on the diagnostic criteria of the American Thoracic Society (2022). Quantitative determination of serum SP-A levels was performed using Cloud-Clone Corp. kits. (China), SP-D and MMP-7 levels using RDS kits (USA), MMP-1 and MMP-9 levels using RayBiotech kits (USA) on the Hydro Flex enzyme immunoassay (TECAN, Austria). Statistical data processing was performed using Statistica 10.0 software. Results. A relationship between elevated MMP-7 and SP-D levels in HP and PPF criteria was found. No statistically significant differences were found between MMP-7 and SP-D levels in IPF and HP with PPF (9.03 ± 3.1 and 8.47 ± 2.61 ng/ml, respectively; p = 0.42), as well as SP-D (34.51 ± 6.12 ng/ml in IPF and 33.22 ± 8.91 ng/ml in HP with PPF; p = 0.45). Negative correlation was noted between elevated levels of SP-D and MMP-7 with FVC and DLCO during the year. Conclusion. An increase in the levels of MMP-7 and SP-D in the blood serum allows us to consider these indicators for the diagnosis of PPF in HP.
- Open Access
- 8 August 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (4) , 476-481
The structure and gender characteristics of progressive pulmonary fibrosis according to retrospective research
Progressive pulmonary fibrosis (PLF) is a group of chronic interstitial lung diseases (ILD) that share common clinical, functional and radiological characteristics and have unfavorable prognosis.The aim was to study the structure and course of PLF in patients with chronic ILD.Methods. A retrospective analysis of 463 medical records of patients with chronic ILD aged 18 to 80 years was carried out for the period from January 2020 to December 2023. PLF was diagnosed based on the criteria of the American Thoracic Society (2022). Statistical data processing was carried out using the Statistica 10.0 program.Results. Signs of PLF were detected in patients with idiopathic pulmonary fibrosis (ILF) in 91.1% of cases, in patients with ILD associated with systemic scleroderma (SSD) – in 71.4% of cases; in patients with hypersensitive pneumonitis (HP), nonspecific interstitial pneumonia (NSIP) and undifferentiated ILD – in 47.5%, 44.4%, and 31.1% of cases, respectively. The progression of pulmonary fibrosis in ILD associated with rheumatoid arthritis (RA) was 16.6%, in sarcoidosis – 2.5%. PLF was statistically significantly more often recorded in men with chronic HP (60% in men vs 40.5% in women; χ2 = 3.4; p = 0.02); and significantly more often in women with unclassified ILD (39% in women vs 24.5% in men; χ2 = 4.2; p = 0.033). Regardless of gender, patients with PLF were older than patients with ILD without signs of PLF (63.1 ± 8.7 years vs 53.8 ± 17.2 years; p = 0.007) Conclusion. Signs of PLF were detected in 32.6% of patients with ILD. The highest incidence of PLF was recorded in the group with ILF and HP, the lowest in lung sarcoidosis. Regardless of gender, patients with ILD and PLF were older than patients without signs of PLF.
- 8 August 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (4) , 476-481
Open AccessThe structure and gender characteristics of progressive pulmonary fibrosis according to retrospective research
Progressive pulmonary fibrosis (PLF) is a group of chronic interstitial lung diseases (ILD) that share common clinical, functional and radiological characteristics and have unfavorable prognosis.The aim was to study the structure and course of PLF in patients with chronic ILD.Methods. A retrospective analysis of 463 medical records of patients with chronic ILD aged 18 to 80 years was carried out for the period from January 2020 to December 2023. PLF was diagnosed based on the criteria of the American Thoracic Society (2022). Statistical data processing was carried out using the Statistica 10.0 program.Results. Signs of PLF were detected in patients with idiopathic pulmonary fibrosis (ILF) in 91.1% of cases, in patients with ILD associated with systemic scleroderma (SSD) – in 71.4% of cases; in patients with hypersensitive pneumonitis (HP), nonspecific interstitial pneumonia (NSIP) and undifferentiated ILD – in 47.5%, 44.4%, and 31.1% of cases, respectively. The progression of pulmonary fibrosis in ILD associated with rheumatoid arthritis (RA) was 16.6%, in sarcoidosis – 2.5%. PLF was statistically significantly more often recorded in men with chronic HP (60% in men vs 40.5% in women; χ2 = 3.4; p = 0.02); and significantly more often in women with unclassified ILD (39% in women vs 24.5% in men; χ2 = 4.2; p = 0.033). Regardless of gender, patients with PLF were older than patients with ILD without signs of PLF (63.1 ± 8.7 years vs 53.8 ± 17.2 years; p = 0.007) Conclusion. Signs of PLF were detected in 32.6% of patients with ILD. The highest incidence of PLF was recorded in the group with ILF and HP, the lowest in lung sarcoidosis. Regardless of gender, patients with ILD and PLF were older than patients without signs of PLF.
- 7 July 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (6) , 34-43
The Joint Role of Serum Markers of Congestion or Myocardial Necrosis And Speckle Tracking Echocardiography in The Detection of Early Subtle Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer
Aim To monitor the dynamics of biomarkers during chemotherapy, targeted chemotherapy and targeted monotherapy in patients with HER2-positive breast cancer (BC); to analyze the emergence timing of these changes; to compare early biochemical and echocardiographic criteria; and to determine the best time for assessing latent subclinical cardiac dysfunction. Material and methods Patients with BC (229 women aged 57±11 years) treated sequentially with anthracyclines, a combination of docetaxel and trastuzumab, and trastuzumab monotherapy were examined during three blocks of BC therapy until the development of clinical cardiotoxicity. Time-related changes in high-sensitivity cardiac troponin I, N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular (LV) global longitudinal strain (GLS) and LV ejection fraction (EF) (up to 12 speckle-tracking echocardiograms/up to 12 laboratory tests) were analyzed. Clinical cardiotoxicity was defined as a symptomatic decrease in LV EF ≥10% from the baseline value of 54% or more. Results Clinically significant cardiotoxicity developed in 6.3-10.9% of cases depending on the treatment option for BC. Early manifestations of cardiotoxicity were detected already at 3 weeks after the start of the first course of chemotherapy. For the BC treatment with anthracyclines and targeted chemotherapy with docetaxel and trastuzumab, the markers of clinical cardiotoxicity were high-sensitivity cardiac troponin I, NT-proBNP and GLS LV. For the trastuzumab monotherapy, only GLS LV had a prognostic value. No statistically significant changes in the concentrations of high-sensitivity troponin I and NT-proBNP were found. Conclusion For timely detection of clinical cardiotoxicity, laboratory tests (high-sensitivity troponin I, NT-proBNP) and echocardiography (GLS LV) are recommended to be performed every 3 weeks before the next course of BC therapy. While doing so, their sensitivity will depend on the treatment option for BC.
- 7 July 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (6) , 34-43
The Joint Role of Serum Markers of Congestion or Myocardial Necrosis And Speckle Tracking Echocardiography in The Detection of Early Subtle Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer
Aim To monitor the dynamics of biomarkers during chemotherapy, targeted chemotherapy and targeted monotherapy in patients with HER2-positive breast cancer (BC); to analyze the emergence timing of these changes; to compare early biochemical and echocardiographic criteria; and to determine the best time for assessing latent subclinical cardiac dysfunction. Material and methods Patients with BC (229 women aged 57±11 years) treated sequentially with anthracyclines, a combination of docetaxel and trastuzumab, and trastuzumab monotherapy were examined during three blocks of BC therapy until the development of clinical cardiotoxicity. Time-related changes in high-sensitivity cardiac troponin I, N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular (LV) global longitudinal strain (GLS) and LV ejection fraction (EF) (up to 12 speckle-tracking echocardiograms/up to 12 laboratory tests) were analyzed. Clinical cardiotoxicity was defined as a symptomatic decrease in LV EF ≥10% from the baseline value of 54% or more. Results Clinically significant cardiotoxicity developed in 6.3-10.9% of cases depending on the treatment option for BC. Early manifestations of cardiotoxicity were detected already at 3 weeks after the start of the first course of chemotherapy. For the BC treatment with anthracyclines and targeted chemotherapy with docetaxel and trastuzumab, the markers of clinical cardiotoxicity were high-sensitivity cardiac troponin I, NT-proBNP and GLS LV. For the trastuzumab monotherapy, only GLS LV had a prognostic value. No statistically significant changes in the concentrations of high-sensitivity troponin I and NT-proBNP were found. Conclusion For timely detection of clinical cardiotoxicity, laboratory tests (high-sensitivity troponin I, NT-proBNP) and echocardiography (GLS LV) are recommended to be performed every 3 weeks before the next course of BC therapy. While doing so, their sensitivity will depend on the treatment option for BC.
- Open Access
- 22 June 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 118-123
Potential of bronchoalveolar lavage in diagnostics of progressive pulmonary fibrosis
Introduction. Progressive pulmonary fibrosis (PPF) represents а poor prognosis in patients with interstitial lung diseases, including hypersensitivity pneumonitis (HP). Currently, along with common functional and radiological diagnostic criteria for PPF, an active search for laboratory biomarkers of PPF is underway.Aim. To study of the dynamic of metalloproteinase levels (MMP-1, MMP-7, MMP-9), monocyte chemoattractant protein-1 (MCP-1) and vascular endothelial growth factor (VEGF) in bronchoalveolar lavage fluid (BAL) and their relationship with IPF criteria in patients with IPF and GP.Materials and methods. The study included 62 patients with ILD over 18 years old, the diagnosis of ILD was established based on the diagnostic criteria of the American Thoracic Society (2022). The levels of markers in bronchoalveolar lavage fluid were determined using Vector-Best kits (Russia) for quantitative determination of MCP-1 and VEGF levels and RayBiotech kits (USA) for determining the level of MMP-1, MMP-7, MMP-9. The study was conducted on a Hydro Flex enzyme immunoassay analyzer (TECAN, Austria). Statistical data processing was performed using the Statistica 10.0 program.Results. Baseline levels of MCP-1, VEGF, MMP-1, MMP-7, MMP-9 in BAL fluid were higher in patients with IPF and PLF in GP compared to patients with GP without signs of PLF. When studying the levels of MMP-7 and VEGF, a reliable association was found between an increase in these biomarkers and a decrease in FVC ≥ 5% and DLCO ≥ 10% of the predicted value within 1 year.Conclusion. Increased levels of MMP-7 and MCP-1 in BAL fluid have an inverse correlation with the dynamics of FVC and DLCO indicators during the year, which corresponds to the FVC criterion.
- 22 June 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 118-123
Open AccessPotential of bronchoalveolar lavage in diagnostics of progressive pulmonary fibrosis
Introduction. Progressive pulmonary fibrosis (PPF) represents а poor prognosis in patients with interstitial lung diseases, including hypersensitivity pneumonitis (HP). Currently, along with common functional and radiological diagnostic criteria for PPF, an active search for laboratory biomarkers of PPF is underway.Aim. To study of the dynamic of metalloproteinase levels (MMP-1, MMP-7, MMP-9), monocyte chemoattractant protein-1 (MCP-1) and vascular endothelial growth factor (VEGF) in bronchoalveolar lavage fluid (BAL) and their relationship with IPF criteria in patients with IPF and GP.Materials and methods. The study included 62 patients with ILD over 18 years old, the diagnosis of ILD was established based on the diagnostic criteria of the American Thoracic Society (2022). The levels of markers in bronchoalveolar lavage fluid were determined using Vector-Best kits (Russia) for quantitative determination of MCP-1 and VEGF levels and RayBiotech kits (USA) for determining the level of MMP-1, MMP-7, MMP-9. The study was conducted on a Hydro Flex enzyme immunoassay analyzer (TECAN, Austria). Statistical data processing was performed using the Statistica 10.0 program.Results. Baseline levels of MCP-1, VEGF, MMP-1, MMP-7, MMP-9 in BAL fluid were higher in patients with IPF and PLF in GP compared to patients with GP without signs of PLF. When studying the levels of MMP-7 and VEGF, a reliable association was found between an increase in these biomarkers and a decrease in FVC ≥ 5% and DLCO ≥ 10% of the predicted value within 1 year.Conclusion. Increased levels of MMP-7 and MCP-1 in BAL fluid have an inverse correlation with the dynamics of FVC and DLCO indicators during the year, which corresponds to the FVC criterion.